Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
This review article focuses on the intrinsic (mitochondrial) pathway of apoptosis, the function of the Bcl-2 protein family that regulates this pathway, the background of the antisense oligonucleotide oblimersen, which targets Bcl-2 protein synthesis, and the implications for this agent in hematologic malignancies.
Tolcher
Anthony W
AW
University of Texas Health Sciences Center, San Antonio, TX 78229, USA. atolcher@idd.org
D017321:Clinical Trials, Phase I as Topic / Q000639:trends; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis*; D016032:Randomized Controlled Trials as Topic / Q000639:trends; D013873:Thionucleotides / Q000235:genetics / Q000627:therapeutic use*
D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D013873:Thionucleotides; C408162:oblimersen